122 related articles for article (PubMed ID: 11301397)
1. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
Nishio K; Nakamura T; Koh Y; Kanzawa F; Tamura T; Saijo N
Cancer; 2001 Apr; 91(8):1494-9. PubMed ID: 11301397
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
[TBL] [Abstract][Full Text] [Related]
3. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
4. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Alli E; Bash-Babula J; Yang JM; Hait WN
Cancer Res; 2002 Dec; 62(23):6864-9. PubMed ID: 12460900
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas.
Chen G; Wang H; Gharib TG; Huang CC; Thomas DG; Shedden KA; Kuick R; Taylor JM; Kardia SL; Misek DE; Giordano TJ; Iannettoni MD; Orringer MB; Hanash SM; Beer DG
Mol Cell Proteomics; 2003 Feb; 2(2):107-16. PubMed ID: 12644570
[TBL] [Abstract][Full Text] [Related]
6. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
Chen S; Zhao Y; Shen F; Long D; Yu T; Lin X
Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
[TBL] [Abstract][Full Text] [Related]
7. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
[TBL] [Abstract][Full Text] [Related]
8. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Chen SZ; Jiang M; Zhen YS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):212-20. PubMed ID: 15812674
[TBL] [Abstract][Full Text] [Related]
9. Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells.
Gradin HM; Larsson N; Marklund U; Gullberg M
J Cell Biol; 1998 Jan; 140(1):131-41. PubMed ID: 9425161
[TBL] [Abstract][Full Text] [Related]
10. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M.
Polzin RG; Benlhabib H; Trepel J; Herrera JE
Gene; 2004 Oct; 341():209-18. PubMed ID: 15474303
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells.
Brattsand G; Roos G; Marklund U; Ueda H; Landberg G; Nånberg E; Sideras P; Gullberg M
Leukemia; 1993 Apr; 7(4):569-79. PubMed ID: 8464235
[TBL] [Abstract][Full Text] [Related]
12. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics.
Marklund U; Larsson N; Gradin HM; Brattsand G; Gullberg M
EMBO J; 1996 Oct; 15(19):5290-8. PubMed ID: 8895574
[TBL] [Abstract][Full Text] [Related]
13. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma.
Friedrich B; Grönberg H; Landström M; Gullberg M; Bergh A
Prostate; 1995 Aug; 27(2):102-9. PubMed ID: 7638082
[TBL] [Abstract][Full Text] [Related]
14. p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest.
Johnsen JI; Aurelio ON; Kwaja Z; Jörgensen GE; Pellegata NS; Plattner R; Stanbridge EJ; Cajot JF
Int J Cancer; 2000 Dec; 88(5):685-91. PubMed ID: 11072234
[TBL] [Abstract][Full Text] [Related]
15. In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells.
Zhao Y; Chen S; Shen F; Long D; Yu T; Wu M; Lin X
Oncol Rep; 2019 Jan; 41(1):501-511. PubMed ID: 30320402
[TBL] [Abstract][Full Text] [Related]
16. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo.
Howell B; Deacon H; Cassimeris L
J Cell Sci; 1999 Nov; 112 ( Pt 21)():3713-22. PubMed ID: 10523507
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells.
Yoshida M; Matsui Y; Ikarashi Y; Usui T; Osada H; Wakasugi H
Anticancer Res; 2007; 27(2):729-36. PubMed ID: 17465195
[TBL] [Abstract][Full Text] [Related]
18. The phenotype of a "Cdc2 kinase target site-deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control.
Marklund U; Osterman O; Melander H; Bergh A; Gullberg M
J Biol Chem; 1994 Dec; 269(48):30626-35. PubMed ID: 7982983
[TBL] [Abstract][Full Text] [Related]
19. Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association.
Larsson N; Segerman B; Gradin HM; Wandzioch E; Cassimeris L; Gullberg M
Mol Cell Biol; 1999 Mar; 19(3):2242-50. PubMed ID: 10022911
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
Tolis C; Photiou A; Camplejohn RS; Retsas S
Anticancer Res; 1993; 13(1):161-6. PubMed ID: 8476208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
